Filing Details

Accession Number:
0001415889-23-011952
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-08 21:05:18
Reporting Period:
2023-08-07
Accepted Time:
2023-08-08 21:05:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1267813 Marinus Pharmaceuticals Inc. MRNS Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1934412 Christina Shafer 5 Radnor Corporate Center, Suite 500
100 Matsonford Rd
Radnor PA 19087
Chief Commercial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-08-07 2,385 $9.52 40,637 No 4 S Direct
Common Stock Disposition 2023-08-08 11 $8.93 40,626 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units.
  2. The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.35 to $9.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
  3. The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $8.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.